Autoimmun Diagnostika

Executive Summary

Autoimmun Diagnostika (AID) is a privately held German biotechnology company that has specialized for over two decades in the development and manufacturing of EliSpot and FluoroSpot assay systems for functional immune response analysis. Founded in 1998 and headquartered in Straßberg, Germany, AID offers a comprehensive portfolio including antigens, ready-to-use kits, automated reader systems, and contract research services. Its core technology enables the quantitative measurement of cytokine or antibody secretion from single T or B cells, serving both research and clinical diagnostic markets. The company's expertise in immunology and diagnostics positions it as a niche player in the growing field of immune monitoring, particularly for infectious diseases, autoimmunity, and oncology. Despite its established presence, AID remains a small private entity without disclosed funding or valuation, which limits its visibility. However, the increasing demand for advanced immunoassays in drug development and personalized medicine presents opportunities. The company's automated readers and comprehensive assay platforms are well-suited to support clinical trials and translational research. To maintain competitiveness, AID will likely need to innovate its product line, pursue regulatory approvals in key markets, and form strategic partnerships. While the company has low market awareness, its long track record and specialized technology provide a solid foundation for growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation automated reader with enhanced sensitivity70% success
• Q4 2026FDA 510(k) clearance for a new diagnostic EliSpot kit targeting infectious diseases40% success
• Q2 2026Strategic partnership with a major pharma company for immuno-oncology monitoring30% success